【ChiCTR1900021995】Retinal Nerve Fiber Layer Optical Texture Signature as a Novel Biomarker for Detection of Glaucoma Progression
ChiCTR1900021995
正在进行
/
/
/
2019-03-19
/
/
青光眼
Retinal Nerve Fiber Layer Optical Texture Signature as a Novel Biomarker for Detection of Glaucoma Progression
Retinal Nerve Fiber Layer Optical Texture Signature as a Novel Biomarker for Detection of Glaucoma Progression
1. To compare the hazard ratios for development of visual field progression upon detection of progressive decline in retinal nerve fiber layer (RNFL) optical texture signature versus upon detection of progressive RNFL thinning 2. To compare the survival distributions between eyes with progressive RNFL thinning and eyes with progressive decline in RNFL optical texture signature 3. To determine the specificities of Trend-based Progression Analysis (TPA) for detection of progressive decline in RNFL optical texture signature and progressive RNFL thinning 4. To measure rates of change of VF mean deviation between eyes with and without progressive decline in RNFL thickness/optical texture signature 5. To measure age-related rates of change of RNFL thickness/optical texture signature 6. To compare the sensitivity and specificity for detection of glaucoma between ROTA and conventional OCT analysis
析因分组（即根据危险因素或暴露因素分组）
其它
N/A
N/A
General Research Fund 2018-19
/
539
/
2019-04-01
2023-06-30
/
The inclusion criteria are: age ≥18 years; best corrected visual acuity (VA) ≥20/40.；
请登录查看The exclusion criteria are: IOP >30mmHg; only one eye with functional vision; inability to perform reliable VF; pathological myopia (eyes with axial length≥26mm with lacquer cracks and chorioretinal atrophy); suboptimal quality of OCT images; previous intraocular surgery other than uncomplicated cataract extraction; and diabetic retinopathy/ maculopathy.；
请登录查看Research Grant Council, University Grants Committee
/
Research Grant Council, University Grants Committee的其他临床试验
香港中文大學眼科學與視覺科學系的其他临床试验
最新临床资讯
-
飞眸医疗首例人体临床试验（FIH）成功开展，国产飞秒屈光设备竞逐540亿屈光市场
动脉网-最新2026-09-10
-
和铂医药：超长效靶向TSLP抗体哮喘二期临床取得阳性结果，三期临床已启动
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
动脉网-最新2026-09-09
-
药明康德2026-09-09
-
一度医药2026-09-08
-
阿斯利康中国2026-09-08
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-09-10
-
2026-09-09
-
2026-09-08
-
摩熵咨询 20 5
-
摩熵咨询 20 8
-
摩熵咨询 34 43
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-09-10
-
2026-09-10
-
2026-09-10
-
摩熵咨询 35 60
-
摩熵咨询 28 52
-
摩熵咨询 34 37
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29